Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity (with Count) Solution Color
Phospho-Tyrosine Mouse mAb (P-Tyr-100) 9411 30 µl
HTScan® Tyrosine Kinase Buffer (4X) 9805 15 ml
DTT (1000X) 80 µl
ATP (10 mM) 9804 1 ml
PYK2 (Tyr402) Biotinylated Peptide 1315 1.25 ml

Product Description

The kit provides a means of performing kinase activity assays with recombinant human Met kinase. It includes active Met kinase (supplied as a GST fusion protein), a biotinylated peptide substrate and a phospho-tyrosine antibody for detection of the phosphorylated form of the substrate peptide.


Molecular Formula:

Peptide substrate, Biotin-Pyk2 (402): 2,166 Daltons. GST-Met: 78 kDa.


Peptide Core Sequence:

DIY*AE


Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits (1,2). The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Research studies have shown that altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, investigators have concluded that Met is an attractive potential cancer therapeutic and diagnostic target (6,7).


1.  Cooper, C.S. et al. (1984) Nature 311, 29-33.

2.  Bottaro, D.P. et al. (1991) Science 251, 802-4.

3.  Bardelli, A. et al. (1997) Oncogene 15, 3103-11.

4.  Taher, T.E. et al. (2002) J Immunol 169, 3793-800.

5.  Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.

6.  Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14.

7.  Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.


Entrez-Gene Id 4233
Swiss-Prot Acc. P08581

Data Sheets & Documentation


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
DELFIA® is a registered trademark of PerkinElmer, Inc.